Pay in 4 interest-free payments of $5.14 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Usually patients will start at a beginning dose level, and depending on their rate of weight loss that dose may be adjusted up
Long-term side effects are less common but can be more significant
REDEFINE 2: Efficacy in Type 2 Diabetes REDEFINE 2, announced in March 2025, addressed a distinct population: 1,206 adults with obesity or overweight and type 2 diabetes across 12 countries, randomised in a 3:1 ratio to CagriSema or placebo for 68 weeks
Pharmacokinetic Duration Why AVP Uses the Designation GLP-3 RT AVP labels this compound GLP-3 RT rather than its generic pharmaceutical name to reinforce that the product sold here is a research chemical, not a prescription drug or compounded pharmaceutical
US$ 24.21
US$ 21.23
US$ 21.89
US$ 21.51
US$ 24.80
